S. Roberts

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

Homie Razavi, Imam Waked, Christoph Sarrazin et al. · Journal of Viral Hepatitis · 2014 · 484 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +16

Sustained virological response rates and durability of the response to interferon‐based therapies in hepatitis C patients treated in the clinical setting

Christopher Desmond, S. Roberts, F. J. Dudley et al. · Journal of Viral Hepatitis · 2005 · 71 citations

Pharmacy, Internal Medicine, Pharmacotherapy +15

1046 FIRST-IN-MAN DEMONSTRATION OF POTENT ANTIVIRAL ACTIVITY WITH A NUCLEOSIDE POLYMERASE (R7128) AND PROTEASE (R7227/ITMN-191) INHIBITOR COMBINATION IN HCV: SAFETY, PHARMACOKINETICS, AND VIROLOGIC RESULTS FROM INFORM-1

Edward Gane, S. Roberts, Catherine Stedman et al. · Journal of Hepatology · 2009 · 63 citations

Medicine, Infectious Diseases, Pharmacology +14

731 Interim results of a multiple ascending dose study of R1626, a novel nucleoside analog targeting hcv polymerase in chronic HCV patients

S. Roberts, Graham Cooksley, David Shaw et al. · Journal of Hepatology · 2006 · 46 citations

Medicine, Infectious Diseases, Pharmacology +14

ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naïve HCV genotype 3-infected patients without cirrhosis

Graham R. Foster, Edward Gane, Armen Asatryan et al. · Journal of Hepatology · 2017 · 39 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14